Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

GENENTECH PRESENTS NEW PHASE III ONE-YEAR DATA FOR VAMIKIBART IN UVEITIC ...

11 October 2026 · By · Wire by Fusion42

Published

11 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at gene.com →

◆ Verified

Fusion42 · 11 October 2026 · Fusion42 review

Genentech presented positive one-year Phase III data for vamikibart treating uveitic macular edema (UME), showing sustained vision improvement and macular thickness reduction. The FDA accepted Genentech's biologics license application with a decision expected by July 2027, potentially establishing vamikibart as the first non-steroid targeted UME therapy.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can now prepare for a shift in uveitis treatment as Genentech moves vamikibart closer to approval, opening the market for non-steroid therapies. If you develop eye disease treatments, start engaging specialists exploring steroid alternatives.

◆ Coverage

1 source · 11 Oct 2026

◆ Related on Wire

◆ Topics

Medtechophthalmologyuveitic-macular-edemadrug-approvalgenentechvamikibart